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Abstract
The remarkable improvement in pediatric cardiosurgery observed over the last few decades has
meant that many patients with congenital heart diseases have entered adult life. The growing
population of adults with congenital heart defects (ACHD) requires specialized treatment. The
team of specialists should consist of cardiologists experienced in congenital heart diseases,
cardiosurgeons, obstetricians and anesthesiologists. The need for providing ACHD with
appropriate healthcare remains largely unmet. The proper care of ACHD requires an excellent
knowledge of defect residuals and post-operative sequel complications. The commonest clinical
problems are arrhythmias, impulse formation and conduction disorders as well as heart
failure with complicated pathophysiology. The medical management of these patients is mainly
based on doctors’ experience, since Evidence Based Medicine recommendations do not cover
the above mentioned clinical issues. Cyanosis must be distinguished as another clinical
problem for which treatment requires special knowledge. For many women with congenital
heart diseases, pregnancy and delivery may be hazardous. To date, observations show that
most patients with congenital heart diseases enjoy a full life. (Cardiol J 2010; 17, 1: 11–19)
Key words: arrhythmia, impulse formation and conduction disorders, cyanosis,
heart failure, pregnancy
The growing population
The extensive progress in cardiology and pe-
diatric cardiac surgery seen in recent decades has
caused more than 85% of children born with con-
genital heart defects (CHD) to reach adulthood. In
order to provide such patients with specialized
health care, attempts are being made to estimate
the discussed population. Congenital heart defects
occur in 4 to 10 per 1,000 live births [1]. According
to Jane Somerville [2] 50% of patients with com-
plex defects, and 90% with simple ones, reach the
eighteenth year of age. Based on this assumption,
estimates of the number of adults with CHD have
been carried out in certain countries [3, 4]. Addi-
tionally, knowing the number of patients under care,
it has been proved that specialized treatment for
these patients, even in highly developed countries,
is definitely insufficient. In most countries, care
does not exceed 50% of needs [1–3]. In western
Poland, for instance, the estimated covered needs
reached merely 10% [4]. Marelli et al. [5] were the
first to provide actual numbers, rather than esti-
mates, thanks to data from the province of Quebec
covering the years 1985–2000. They have drawn
several conclusions based on these numbers: 85%
of children with CHD reach maturity, adults with
heart defects outnumber infants with similar ano-
malies, and the age of the analyzed population increas-
es systematically, with most of the patients reach-
ing the fourth decade of life. About 5% of patients
reach 60 years of age, which inevitably leads to the
occurrence of additional age-related illnesses [3, 6].
The researchers from Montreal [7] analyzed
the demand for medical care among adults with
CHD and came up with the following findings: 87%
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of patients visited outpatient clinics, 51% required
hospitalization with some of them necessitating
intensive care (16%). The study also revealed that
patients before 65 years of age required specialized
treatment considerably more often than the remain-
ing population of cardiac patients, which emphasiz-
es the need for comprehensive medical care [8].
It was also estimated that a cardiologic center dedi-
cated to adults with CHD should meet the demands
of a 4–6 million population. The staff in such cen-
ters must constitute cardiologists who are experi-
enced in the discussed issue, as well as cardiosur-
geons and interventional cardiologists who have
knowledge of heart defects anatomy, expected com-
plications, and post-operative residuals, all of which
enables the performance of necessary surgery.
It is also essential for the treating team to include
obstetricians and anesthesiologists familiar with
CHD, as well as counseling psychologists and
a well-trained nursing team [9].
What increases the complexity of the problem
is the variety of anatomical heart anomalies present
in the adult population with congenital heart dis-
ease. The most numerous group consists of patients
who were operated on in the past. Within this group,
there is a further distinction between those treat-
ed with older or newer surgical techniques, which
bring about different clinical outcomes. The results
of the primary and contemporary ways of defects
correction are indeed incomparable [10, 11]. Anoth-
er group consists of patients who were not subject-
ed to cardiac surgery because it was unnecessary.
Another group comprises patients where there was
no possibility of surgery, or there were contraindi-
cations to surgery, of which pulmonary hyperten-
sion was the most frequent [3, 6, 9, 12]. At present,
primary surgeries (e.g. Fallot tetralogy repair) are
performed in specialized centers. However patients
are more and more often undergoing re-operation.
This may be a scheduled surgery being the next
stage of cardiosurgery (e.g. Fontan operation after
Glenn procedure), unavoidable like a consecutive
surgery in ever-progressing disease (e.g. implan-
tation of aortic prosthesis after original valvuloto-
my), or unexpected operation (e.g. renewed septal
defect, pulmonary stenosis or aortic regurgitation
after arterial switch operation) [13].
Cardiac surgery performed in adults with CHD
requires of an operating surgeon special skills, ex-
cellent knowledge of a defect’s anatomy, way of
performing the surgery, and the type of possible
complications from the previous surgery. Overall
perioperative mortality ranges from 2% to 5% and
increases with each subsequent surgery as some
patients undergo repeat sternotomy [12]. The Ca-
nadian authors proved what could have been intu-
itively predicted: that significantly better post-
-operative results are achieved when operations are
performed by cardiac surgeons acquainted with
children’s cardiosurgery [14].
Clinical complications
— residuals and sequels
Rational care for adults with CHD may turn out
to be demanding as it requires not only exact knowl-
edge of a defect’s anatomy and means of correction,
but also the ability to predict its hemodynamic con-
sequences appearing within a specific period of
time. Such care demands familiarity with potential
post-operative complications and anatomical rem-
nants of defect, so called residua and sequelae
[2, 15–17].
Arrhythmia
The commonest clinical problems, and so the
commonest cause of death in the discussed popu-
lation, are heart rhythm disorders. Usually they are
the first sign of hemodynamic abnormality. They
occur in up to 40% of patients after 50 years of age,
which in the light of an aging population creates an
essential therapy problem. Arrhythmia, for instan-
ce, judged to be mild in the so called average popu-
lation, may cause substantial clinical consequences
in adults with CHD. This is why understanding its
pathophysiology and ability to treat it are so crucial
[3, 15, 17].
Supraventricular arrhythmia has been viewed
as the ’price’ of long-term survival after surgery
performed in the past. Modern operations decrease
the incidence of these complications [17]. Examples
are: replacement of Sennig/Mustard operation with
an arterial switch method [18]; modifications of
Fontan procedure such as total cavopulmonary con-
nection which do not remodel right atrium; and
avoidance of transannular patch in the right ventri-
cle outflow tract in tetralogy of Fallot that reduces
arrhythmogenic pulmonary regurgitation [19, 20].
In general, pathogenesis of supraventricular ar-
rhythmia in adults with congenital heart defects is
compound and stems from a) primary alterations in
conductive fibres route; b) enlargement of atria
causing dilation, fibrosis, increased wall stress and
finally inhomogeneous electrical activity; c) pres-
ence of surgical scars that favor delay in impulse
conduction resulting in intra-atrial re-entrant
tachycardia (IART); d) deterioration in ventricle
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function: supraventricular arrythmia is the effect of
abnormal hemodynamics and can also lead to fur-
ther exacerbation in heart failure; and e) sinus node
dysfunction which promotes re-entrant arrhythmias
[16, 17, 20–22].
The peculiarity of anatomical anomalies caus-
es different incidence of certain supraventricular
arrhythmias, in particular congenital heart defects.
For example, arrhythmia resulting from accessory
pathways is typical of Ebstein’s anomaly and con-
genitally corrected transposition of great arteries.
Intra-atrial re-entrant tachycardia, arrhythmia clin-
ically resembling slower atrial flutter, occurs usu-
ally in patients with both transposition of great ar-
teries after Mustard/Sennig operation and/or
univentricular heart after Fontan procedure. The
least frequent in this group of patients is atrial fi-
brillation, which is typical of ‘left’ heart diseases,
such as defects of aortic or mitral valves [17, 19,
23, 24].
As it follows from thepathogenesis presented
above, treatment of supraventricular arrhythmia
should in the first place entail correction of possi-
ble hemodynamic complications. In the case of
a sudden onset of atrial fibrillation or flutter, cardio-
version is the most recommended initial treatment
of choice despite high risk resulting from incom-
plete anticoagulation therapy [2, 17]. Pharmacother-
apy in patients with CHD is mostly extrapolated
from average population since there are no avail-
able studies based on Evidence Based Medicine
(EBM) recommendations [17, 25]. It is important
to avoid negative inotropic agents: thus digitalis and
amiodarone would be recommended. On the one
hand, those drugs should be administered with cau-
tion, especially in cyanotic patients; but on the oth-
er hand, amiodarone is known to be the most suc-
cessful agent in preventing supraventricular ar-
rhythmia recurrence, so dangerous in the discussed
population [3]. In spite of full pharmacological treat-
ment, however, clinical practice shows that IART
recurs in 70% of patients after two years [26]. Im-
plantation of a pacemaker is yet another preventive
measure undertaken against supraventricular ar-
rhythmia, as the device eliminates excessive brady-
cardia and prevents its intensification during phar-
macotherapy [27]. Catheter ablation ranks as
a modern and widely used form of treatment in the
above mentioned arrhythmia. It must be empha-
sized that this procedure should be carried out ex-
clusively in highly-specialized centers because it
requires exact knowledge of both a defect’s anato-
my and its former surgical repair.
Unfortunately, therapeutic effects are still not
satisfactory: IART ablation success is almost 90%
but this is a short-term outcome. Also, primarily
successful ablation of accessory pathways in Eb-
stein’s anomaly ends up with arrhythmia recurrence
in 25% of patients within months. Ablation is least
effective in patients with univentricular heart after
Fontan procedure [26–28], most likely due to ana-
tomical complexity of the defect. In treatment of
supraventricular arrhythmia, consideration should
also be given to surgical ablation during atrial maze
operation. However, any decision about surgery
must be well thought out as it entails undergoing
another operation and the recurrence of arrhythmia
still scores several per cent [17, 19].
As for the occurrence of ventricular arrhyth-
mias, they are rare among adults with congenital
heart defects, and mostly recorded in patients af-
ter Fallot repair and with left ventricular outflow
tract defects [17, 24]. Such arrhythmia may contri-
bute to sudden cardiac death [15, 16]. which affects
5% of patients after Fallot repair [29]. The patho-
genesis of ventricular arrhythmia in patients with
congenital heart defect is still under investigation.
However, it is assumed that ventricular arrhythmia
results from: a) presence of scar after ventriculot-
omy creating substrate for re-entry circuit; b) fibro-
sis of myocardium due to long lasting cyanosis;
c) valvular regurgitations causing ventricle’s dilation,
increased stress of its walls and inhomogeneous
electrical activity regions; and d) way of myocardi-
um protection during operation. Moreover, in pa-
tients with Fallot’s tetralogy, a contributory factor
may be pulmonary regurgitation and right bundle
branch block that conduce re-entry circuit, especial-
ly in the presence of a scar [17, 30]. Treatment of
ventricular arrhythmia, similarly to supraventricu-
lar, requires, in the first place, hemodynamical cor-
rection of the defect (e.g. valve replacement, clo-
sure of residual shunt or widening of conduit)
[3, 15, 19, 20]. Pharmacotherapy is applied according
to the same principles as in supraventricular ar-
rhythmia treatment, where experience is extrapo-
lated from the average population and treatment is
based on the exclusion of negative inotropic agents.
There is still no appropriate data resulting from
studies based on EBM available. Ablation procedure
is performed in rare cases (in tetralogy of Fallot
short-term success rates are 80%, with recurrence
amounting only to 20%) [26, 31]. There is increas-
ing use of implantable cardioverter-defibrillators
(ICD). Such devices are applied predominantly in
patients after Fallot repair, with congenitally cor-
14
Cardiology Journal 2010, Vol. 17, No. 1
www.cardiologyjournal.org
rected transposition of great arteries and complex
aortic defects. The young age of patients and fre-
quent sinus tachycardia, however, are likely to re-
sult in the numerous inappropriate shocks that were
observed in 25%. In adults with CHD, ICD has prov-
en value in secondary prevention. Nonetheless,
clinical features justifying primary prevention are
still sought in this group of patients [32].
Impulse formation and
conductions disorders
A serious and frequent problem pertaining to
the analyzed population is usually impulse forma-
tion and conduction disorders. Congenital anomaly
of sinus node is observed in heterotaxy syndrome,
whereas acquired type of this dysfunction is char-
acteristic of both Mustard/Sennig operation for
transposition of great arteries and Fontan operation
[17]. Congenital atrio-ventricular block develops
most notably in common atrio-ventricular canal,
congenitally corrected transposition of great arter-
ies, and in Ebstein’s anomaly. Acquired atrio-ven-
tricular block may result from closure of ventricu-
lar septal defects, surgery for left-heart outflow
tract obstruction, as well as aortic valve replace-
ment [16, 33]. Some of these patients require per-
manent pacemaker implantation.
This surgery, similarly to other procedures
mentioned above, calls for special skills on the part
of the cardiologist. Performing the procedure, elec-
trophysiologists must take potential obstacles into
consideration: a) persistent left superior vena cava
and often concomitant extreme dilation of coronary
sinus changing the route of lead implantation; b) the
possibility of post-operative narrowing of superior
vena cava; and c) absence of venous chamber ac-
cess in patients after Fontan repair. Because of
those hazards, an epicardial approach is still applied
in many patients. This procedure, nonetheless, is
not free of risks: greater probability of lead dam-
age, higher stimulus threshold which is decreased
through the application of steroid-eluting features,
and finally the necessity of thoracotomy that is
risky, especially in cyanotic patients [34]. Due to
its physiological pacing mode, particularly dual-
chamber, the endocardial approach would be pre-
ferable [33]. Implanting ventricular leads is yet an-
other challenge, especially when treating patients
after Mustard/Sennig operation. They may some-
times need dilation of tight obstruction along the
upper limb of the baffle. It is also vital to place the
lead properly in morphological left ventricle. An
effective solution for difficult anatomical anomalies
seems to be an appliance of hybrid stimulation,
where one lead is epicardial whereas the other is
placed into the coronary sinus [26]. Furthermore,
it must be borne in mind that patients with intrac-
ardiac shunts who require endocardial pacing must
undergo anticoagulant therapy [35].
Heart failure
The most frequently observed symptom in
adults with CHD is heart failure. Defining heart fail-
ure in this group of patients is particularly difficult.
The state may be caused by deterioration in func-
tion of only right or single ventricle, shunting of
arterial and venous blood, and/or increased pressure
and resistance in pulmonary circulation. All these
clinical features decrease exercise capacity and in-
fluence outcomes of objective oxygen consumption
parameters [36]. Patients with CHD easily adapt to
exercise intolerance, and by reducing daily activi-
ties they miss symptoms of successive deteriora-
tion in physical efficiency. This improves their dai-
ly quality of life, but on the other hand misleads the
doctor in charge. However, such asymptomatic pa-
tients have been proved to have decreased oxygen
consumption [37, 38]. Furthermore, a spiroergo-
metric test, an objective tool, reveals lower oxygen
consumption in patients with complex heart defects,
cyanosis, pulmonary hypertension or atrial flutter/
/fibrillation [39, 40]. Pathogenesis of heart failure
in adults with CHD is complex and consists of: a) de-
crease in contractility of heart ventricle or both
ventricles; b) pressure and/or volume overload;
c) myocardial ischemia resulting from coronary ar-
teries anomalies or damage during surgical proce-
dure like arterial switch in transposition of great ar-
teries or tetralogy of Fallot operation; d) insufficient
protection of myocardium during cardiosurgery; and
e) function deterioration of morphologic right ven-
tricle in systemic position after Mustard/Sennig
operation or in congenitally corrected transposition
of great arteries [36].
Pharmacological treatment of heart failure in
the discussed population is derived from the scant
studies that are mostly unrelated to EBM recom-
mendations. Only the research concerning losartan
[41] and carvedilol [42] meets these requirements.
Efficacy of these drugs, however, was not confirmed
in patients with CHD. This is why the therapy is
based on generally accepted principles that are
adopted in the treatment of left ventricle heart fail-
ure. However, some distinctions and restrictions
must be underlined: administration of angiotensin-
-converting enzyme inhibitor in cyanotic patients
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due to Eisenmenger syndrome may result in worse-
ning right-to-left shunting due to concurrent re-
duction in systemic vascular resistance and there-
fore blood oxygenation decreases. Furthermore,
beta-blockers alone, or in combination with an an-
giotensin-converting enzyme inhibitor, should be
very carefully prescribed in adults with CHD, es-
pecially patients with left ventricle dysfunction, as
observed in aortic coarctation, Marfan syndrome or
subaortic stenosis. Furthermore, the efficacy of dis-
cussed drugs has not been demonstrated in patients
with systemic morphologic right ventricle and sin-
gle ventricle [43].
An isolated record shows positive results of
aldosterone antagonists applied for patients after
Fontan repair with protein-losing enteropathy [44].
Particular caution is required during the adminis-
tration of diuretics. This mainly concerns patients
dependent on preload such as adults after Fontan
or Mustard/Sennig procedure or cyanotic patients
where application of diuretics may lead to a danger-
ous increase in blood viscosity [16]. Besides, at-
tempts at resynchronization therapy are being
made. They predominantly affect patients after op-
eration for tetralogy of Fallot and congenitally cor-
rected transposition of great arteries. The results
are promising, as improvement of heart function
was observed irrespective of a left or right ventricle
functioning as the systemic pumping chamber [45].
Invasive treatment is applied more and more
often in adults with CHD. The benefit of that kind
of treatment is prevention of thoracotomy and bur-
den of extracorporeal circulation. Long-term obser-
vation lays basis for the claim that interventional
treatment is a procedure of choice in pulmonary
stenosis, ostium secundum atrial septal defect, re-
coarctation of aorta and patent ductus arteriosus
[46]. Treatment of native coarctation of aorta shows
positive effects and its results are comparable to
a surgical approach [47]. Transcatheter closure of
ventricular septal defects poses a 5% risk of late
complete atrio-ventricular block. That is why clo-
sure of only muscular septal defects is safe [11].
Aortic balloon valvuloplasty in the discussed popu-
lation is considered only in particular circumstanc-
es, namely in case of contraindicated surgery or
pregnancy. These limitations result from poor out-
comes of the procedure: i.e. restenosis observed in
up to 40–50% within five to ten years, and/or exac-
erbation of aortic regurgitation. When performed by
an experienced cardiologist, good results are ob-
tained in angioplasty of pulmonary arteries stenos-
is due to residuals after performed operation or
palliative procedure. An alternative to surgery of an
increased risk is the possibility of percutaneous
dilatation of both conduits (connecting subpulmo-
nary ventricle to pulmonary artery after Fontan
procedure) and baffle obstruction after Mustard/
/Sennig operation [46].
The ultimate therapeutic option is heart, lung,
or heart-lung transplantation. About 10–20% of pa-
tients with congenital heart defects, at a certain
stage of life, are estimated to be selected for such
treatment. Survival rates, in specialized centers, are
comparable to the outcomes of this therapy in the
average population: they equal about 75% after one
year and 60% after five years. It must be stressed
that frequently distorted vascular anatomy, as ob-
served in transposition of great arteries or after
Fontan repair, creates additional intraoperative
surgical obstacles [48].
Cyanosis
A particular condition in patients with CHD
constitutes cyanosis. It occurs due to blood desat-
uration resulting from reduction in pulmonary blood
flow (in primary cyanotic defects like tetralogy of
Fallot or transposition of great arteries) or as the
consequence of secondary pulmonary hypertension,
present mostly in simple shunt lesions. Adults with
primary cyanotic defects are extremely rare, as
most of them undergo surgery in early childhood.
The few that reach adulthood without such an ope-
ration are those in whom the balance between size
of ventricular septal defect and pulmonary stenos-
is is preserved. The balance provides adequate tis-
sue oxygenation and cardiac output, yet does not
affect pulmonary hypertension. Secondary pulmo-
nary hypertension is observed in 5–10% of congen-
ital heart defects; among them the percentage of
patients with complex defects after palliative pro-
cedures is still increasing [1–4, 16]. Clinical presen-
tation of cyanosis affects multiple organs and results
from secondary erythrocytosis due to the raised
production of erythropoietin. Augmented haemo-
globin production is an adaptive mechanism guar-
anteeing adequate tissue oxygenation. Increased
hematocrit leads to blood hyperviscosity followed
by specific clinical symptoms, such as headaches,
vertigo, visual disturbances, paresthesias and
myalgias.
An additional cause of some of these symptoms
is iron deficiency, observed mainly in patients who
underwent phlebotomy. Due to a lowered count and
dysfunction of platelets, as well as disruption of in-
trinsic pathway (reduction of activation of II, VII,
IX, X, V and von Willebrand factors), cyanotic
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patients often exhibit bleeding and thromboembolic
complications such as stroke, pulmonary bleeding
and large pulmonary vessel thrombosis. Also, the
risk of intraoperative bleeding rises substantially in
such patients owing to the excessive net of small
vessels. Moreover, an increased heme breakdown
facilitates hyperuricemia and eventually joint and
kidney changes related to gout. Impairment of he-
patic function, associated with bilirubin elevation,
leads to cholecystitis, often followed by cholangi-
tis. Kidney dysfunction is often observed as a re-
sult of secondary glomerulopathy. Finally, cyanot-
ic patients are at risk of developing infective en-
docarditis, cerebral abscess and pneumonia [16].
The basic procedure that guarantees rational
care of cyanotic patients with CHD is a referral to
a specialized center, since it is commonly known that
the most effective treatment couples with experi-
ence in a given area [1–4]. The situation is that gen-
eral practitioners or even cardiologists who are not
trained in congenital heart defects, may encounter
only a few patients with secondary pulmonary hy-
pertension in their careers due to the rarity of
Eisenmenger syndrome. As Somerville [2], a pio-
neer practitioner and a source of knowledge con-
cerning adolescents with congenital heart defects
aptly noted, doctors commit a gross mistake when
they avoid referring discussed patients to special-
ists and keeping them as ‘rare stamps in an album’.
General recommendations, so essential in this
group, include instructing patients on safe lifestyles
which entails abstaining from physical exertion that
could lower systemic pressure and enhance right
to left shunt followed by decreased saturation. Be-
sides, high pulmonary resistance hinders addition-
al left atrial and ventricular inflow, which results in
a drop in ejection fraction. Furthermore, staying in
a high temperature should be avoided as dehydra-
tion increases hematocrit (and consequently blood)
viscosity. This issue is worth discussing with, most-
ly young, patients with CHD since deaths at the
disco are quite often observed in adolescents with
CHD [49]. Hypovolemia resulting from diarrhea,
vomiting or fever requires immediate infusion with
fluids [16].
The method too often applied by general prac-
titioners in a case of cyanosis is phlebotomy. It
needs to be emphasized that this procedure is only
recommended in coexistent symptoms of excessive
blood viscosity observed with hematocrit exceed-
ing 65%. This is due to its serious side effect which
is iron deficiency anemia resulting in microcytosis
aggravating thrombotic complications. The condi-
tion remains frequently undiagnosed as the hemo-
globin equaling 15 g/dL, in healthy patients assessed
as a normal value, is however in cyanotic patients
insufficient, as the border line for them aproximates
18 g/dL. Contrary to previous suspicions, increased
hematocrit does not lead to dangerous strokes. The
risk factors for named complications are iron defi-
ciency, arterial hypertension and atrial fibrillation
[50]. During the procedure, blood withdrawal should
not exceed 250 to 500 mL and additionally it should
be replaced with concomitant intravenous saline
volume ranging from 750 to 1,000 mL. Moreover,
no more than four phlebotomies can be performed
yearly. If clinical improvement does not occur, the
reason may be iron deficiency anemia that necessi-
tates the prescription of oral ferrous sulfate (325 mg
daily). It is justified to perform phlebotomy pre-
operatively in order to improve hemostasis [16].
The issue of anticoagulation therapy remains
unresolved. Due to increased thrombotic and bleed-
ing risk in cyanotic patients, treatment with cou-
marin derivatives is accepted only in atrial fibrilla-
tion, intracardiac mechanical prostheses and con-
duits accompanied by advanced heart failure.
Indications for such treatment are episodes of mas-
sive pulmonary thrombosis, observed in about 30%
of patients with Eisenmenger syndrome. Howev-
er, a great expert on that topic, Perloff et al. [51], is
against administration of coumarin derivatives even
in such settings. He claims that antithrombotic
agents may lead to almost intractable pulmonary
hemorrhage [52]. A frequent and life-threatening
clinical complication is hemoptysis. The condition
requires adequate therapeutic approach including
hospitalization, physical activity limitation and
cough reflex elimination. In an advanced case, fresh
frozen plasma, platelet mass, vitamin K, factor VIII,
or ultimately cryoprecipitate should be secured.
Bronchoscopy is definitely contraindicated as it
does not provide substantial data and at the same
time may be a potential source of pulmonary hem-
orrhage. High risk of serious pulmonary infections
necessitates flu and anti-pneumococci vaccination
[53]. Oxygen administration does not usually lead
to increased saturation but can result in dangerous
airway mucosal dehydration [54].
The importance of highly-specialized centers
must be also mentioned when talking about the
treatment of cyanotic patients. Non-cardiac surger-
ies in cyanotic adults with CHD must only be per-
formed in such centers, providing adequate anes-
thesia, as they account for the most frequent cause
of death in this population. Anesthetics which re-
duce blood pressure to the least extent should be
administered so as not to aggravate right-to-left
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shunting and in consequence desaturation. On the
other hand, a sudden rise in resistance may lead to
right ventricular failure. Other dangers concern
intraoperative arrhythmias, significant blood loss
and bleeding complications typical of cyanosis. For
that reason, local anethesia is the preferable option.
Epidural anesthesia should not supplant general
anesthesia due to the increased hypotensive effect
and bleeding risk. Lastly, an important role in cy-
anosis treatment is played by intraoperative moni-
toring, as it helps to evaluate volemia and pressure
changes as well as pulse oximetry in order to as-
sess oxygen saturation [55].
Pharmacotherapy of pulmonary hypertension
is still at the stage of clinical analysis. Progress in
the pathophysiology study of pulmonary hyperten-
sion, observed in recent decades, has resulted in
the introduction of new groups of agents: prostacy-
cline derivatives (Epoprostenol, Treprostinil, Bera-
prost, Illoprost), phosphodiesterase inhibitors
(Sildenafil, Tadalafil), endothelin receptor antago-
nists (Bosentan, Sitaxantan, Ambrisentan) or nitric
oxide. These drugs should be exclusively adminis-
tered to patients in NYHA functional class III and
IV [53]. The named drugs reduce not only pulmo-
nary but also systemic pressure; hence they poten-
tially increase right-to-left shunting and in turn pro-
duce diverse results in patients with Eisenmenger
syndrome. For the time being, only Bosentan has
proved effective in this population [56].
Pregnancy
Pregnancy and the moment of delivery pose an
enormous risk for female cyanotic patients. The risk
increases with the degree of desaturation. In pa-
tients with blood saturation below 85% maternal
mortality reaches 50%, which is similar to the per-
centage of spontaneous abortion [57]. Conception
is contraindicated in advanced cyanosis, which ad-
ditionally constitutes one of the few cardiologic in-
dications to pregnancy termination [58]. Such a dra-
matic decision is also justified in patients with ad-
vanced heart failure, severe aortic stenosis, and in
Marfan syndrome when aortic root diameter ex-
ceeds 45 mm [59]. Pregnancy in patients with oth-
er congenital heart defects is usually well tolerat-
ed, although it may become problematic due to he-
modynamic changes. During pregnancy, increased
blood volume and tachycardia, as well as decreased
systemic vascular resistance, are observed [60].
Metaanalysis reported on about 2,500 patients with
congenital heart defects [61] showed that serious
cardiologic complications, like significant arrhyth-
mia, heart failure, myocardial infarction, stroke, or
even death, were noticed in 11% of women, mostly
patients with the following conditions: cyanosis,
univentricular heart, congenitally corrected trans-
position of great arteries after Mustard/Sennig pro-
cedure, truncus arteriosus, common atrio-ventric-
ular canal and after Fontan repair. Spontaneous
abortions occur more frequently than in the aver-
age population (15% vs 10–12%). Therefore, a mul-
tidisciplinary approach including the assistance
of experienced cardiologists, obstetricians and an-
esthesiologists is required [62]. The risk of possi-
ble complications during pregnancy and delivery is
reduced by adequate cardiologic assessment and
possible correction of existing hemodynamic disor-
ders before conception. It is also crucial to discuss
with young women possible complications and the
probability of heart anomaly inheritance [63]. Preg-
nancy should be strongly discouraged particularly
in the above mentioned cases; however no available
contraceptive method is optimal in this setting. The
adverse effects of oral contraceptives should be
borne in mind as an estrogen-related raised risk of
thrombotic complications and a progesterone-relat-
ed increase in blood volume may exacerbate symp-
toms of heart failure. However, contraception in
high-risk patients is less risky than possible preg-
nancy [64].
Survival
The degree of hazard in a given population is
measured by the number of recorded deaths. The
discussed population constitutes mainly adoles-
cents; thus mortality rate in this group is lower than
in other groups with frequently analyzed cardiologic
diseases. The data shows mortality in patients with
CHD is relatively low and averages about 4.5% af-
ter tenyears of follow-up; only in the group of com-
plex defects does it exceed 10% [65]. Sudden deaths
have been proved to occur 25 to 100 times more
often than in the average population. Moreover, this
negative outcome may even appear in the second
decade of life, mainly in patients with cyanosis and
after systemic ventricle outflow repair [66]. The
exact data collection and analysis concerning sur-
vival rate in patients with congenital heart defects
are cumbersome, due to the small number, great
variety of population, as well as freqent out-of-hos-
pital deaths. Attempts are being made to determine
the factors of death risk in this population. Some
researchers suggest age and cyanosis [67] as the
important factors, others point to post-operative
complications or declining heart failure [49].
18
Cardiology Journal 2010, Vol. 17, No. 1
www.cardiologyjournal.org
Challenges
Regardless of all the symptoms discussed
above, due to the earlier efforts of pediatric cardio-
surgeons and pediatricians, the great majority of
adults with congenital heart defects experience
a full life. This is why close and careful medical man-
agement, as well as collection and study of data, are
so crucial.
Rational care for adults with congenital heart
defects constitutes a great contemporary challenge,
similar to the one posed by creators of new cardio-
surgical techniques, as to how best to prolong the
effect of their brilliant work.
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